Tempus AI, a health-care diagnostics company that uses AI to interpret medical tests to help physicians provide more accurate treatment for their patients, rose by as much as 15% in its Nasdaq Stock Market trading debut on Friday, after going public under the ticker symbol "TEM."
Tempus AI priced 11.1 million shares at $37 apiece on Thursday, at the top of its initial $35 to $37 target range.
Its early gains, if they hold, would place the company at a valuation of roughly $7 billion.
Tempus believes that AI can help guide therapy selection and treatment decisions, in conjunction with the patient's doctor.
"We're on a really good trajectory," Tempus AI CEO Eric Lefkofsky said on CNBC's "Squawk Box" Friday morning before shares started trading.
Persons:
Eric Lefkofsky, we're
Organizations:
Nasdaq Stock Market